Relevance of ARID1A Mutations in Endometrial Carcinomas
暂无分享,去创建一个
D. Santini | F. Musiani | S. Angelini | G. Tallini | A. Perrone | C. Ceccarelli | A. De Leo | D. de Biase | F. Rosini | P. De Iaco | C. Zamagni | M. Visani | A. G. Corradini | G. Ravegnini | T. Maloberti | V. Sanza | Marco Grillini | Viviana Sanza
[1] P. Hrelia,et al. Identification of miR-499a-5p as a Potential Novel Biomarker for Risk Stratification in Endometrial Cancer , 2021, Frontiers in Oncology.
[2] P. Hrelia,et al. Can miRNAs be useful biomarkers in improving prognostic stratification in endometrial cancer patients? An update review , 2021, International journal of cancer.
[3] Shouying Xu,et al. The Role of ARID1A in Tumors: Tumor Initiation or Tumor Suppression? , 2021, Frontiers in Oncology.
[4] Yina Gao,et al. Downregulated ARID1A by miR-185 Is Associated With Poor Prognosis and Adverse Outcomes in Colon Adenocarcinoma , 2021, Frontiers in Oncology.
[5] A. Brandes,et al. Molecular alterations in pancreatic tumors , 2021, World journal of gastroenterology.
[6] G. Troncone,et al. Multi-gene custom panels for the characterisation of metastatic colorectal carcinoma in clinical practice: express the role of PIK3CA mutations , 2021, Journal of Clinical Pathology.
[7] D. Santini,et al. What Is New on Ovarian Carcinoma: Integrated Morphologic and Molecular Analysis Following the New 2020 World Health Organization Classification of Female Genital Tumors , 2021, Diagnostics.
[8] D. Bowtell,et al. Treatment Strategies for ARID1A-Deficient Ovarian Clear Cell Carcinoma , 2021, Cancers.
[9] D. Santini,et al. ARID1A and CTNNB1/β-Catenin Molecular Status Affects the Clinicopathologic Features and Prognosis of Endometrial Carcinoma: Implications for an Improved Surrogate Molecular Classification , 2021, Cancers.
[10] S. Piana,et al. Immunohistochemical Biomarkers as a Surrogate of Molecular Analysis in Ovarian Carcinomas: A Review of the Literature , 2021, Diagnostics.
[11] F. Dimaio,et al. A Structural Model of the Endogenous Human BAF Complex Informs Disease Mechanisms , 2020, Cell.
[12] A. Giordano,et al. An Analysis of Clinical, Surgical, Pathological and Molecular Characteristics of Endometrial Cancer According to Mismatch Repair Status. A Multidisciplinary Approach , 2020, International journal of molecular sciences.
[13] G. Tallini,et al. Molecular Diagnostic of Solid Tumor Using a Next Generation Sequencing Custom-Designed Multi-Gene Panel , 2020, Diagnostics.
[14] V. Balis,et al. Diagnostic significance and prognostic role of the ARID1A gene in cancer outcomes (Review) , 2020 .
[15] Peter B. McGarvey,et al. Proteogenomic Characterization of Endometrial Carcinoma , 2020, Cell.
[16] Yanhui Xu,et al. Structure of nucleosome-bound human BAF complex , 2020, Science.
[17] A. Gavin,et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. , 2018, European journal of cancer.
[18] Radhika Mathur. ARID1A loss in cancer: Towards a mechanistic understanding , 2018, Pharmacology & therapeutics.
[19] S. Miyamoto,et al. Massively parallel sequencing of cell-free DNA in plasma for detecting gynaecological tumour-associated copy number alteration , 2018, Scientific Reports.
[20] Helen M Berman,et al. Development of a Prototype System for Archiving Integrative/Hybrid Structure Models of Biological Macromolecules. , 2018, Structure.
[21] R. Bernards,et al. ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors , 2018, Oncogene.
[22] Melissa Matz,et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries , 2018, The Lancet.
[23] A. Talhouk,et al. Confirmation of ProMisE: A simple, genomics‐based clinical classifier for endometrial cancer , 2017, Cancer.
[24] K. Wong,et al. Loss of ARID1A expression leads to sensitivity to ROS-inducing agent elesclomol in gynecologic cancer cells , 2016, Oncotarget.
[25] H. Putter,et al. Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts , 2016, Clinical Cancer Research.
[26] D. Aoki,et al. ARID1A gene mutation in ovarian and endometrial cancers (Review) , 2015, Oncology reports.
[27] L. Wood,et al. Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis , 2015, Oncotarget.
[28] Wei Zhang,et al. ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors. , 2015, Cancer discovery.
[29] A. Talhouk,et al. A clinically applicable molecular-based classification for endometrial cancers , 2015, British Journal of Cancer.
[30] Steven L Salzberg,et al. HISAT: a fast spliced aligner with low memory requirements , 2015, Nature Methods.
[31] S. Salzberg,et al. StringTie enables improved reconstruction of a transcriptome from RNA-seq reads , 2015, Nature Biotechnology.
[32] W. Huber,et al. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.
[33] P. Goodfellow,et al. Evaluation of incidence and prognostic significance of newly identified hotspot mutations in DNA polymerase epsilon (POLE) in endometrial cancer: Contextualizing findings from The Cancer Genome Atlas Research Network , 2014 .
[34] H. Morreau,et al. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer , 2013, Modern Pathology.
[35] Steven J. M. Jones,et al. Integrated genomic characterization of endometrial carcinoma , 2013, Nature.
[36] M. Takano,et al. Complete remission of recurrent ovarian clear cell carcinoma by chemotherapy with bevacizumab, trabectedin and oxaliplatin , 2013, The journal of obstetrics and gynaecology research.
[37] S. Wiseman,et al. Loss of BAF250a (ARID1A) is frequent in high‐grade endometrial carcinomas , 2011, The Journal of pathology.
[38] I. Shih,et al. Mutation and Loss of Expression of ARID1A in Uterine Low-grade Endometrioid Carcinoma , 2011, The American journal of surgical pathology.
[39] T. Goto,et al. Weekly administration of temsirolimus for heavily pretreated patients with clear cell carcinoma of the ovary: a report of six cases , 2011, International Journal of Clinical Oncology.
[40] Conrad C. Huang,et al. UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..
[41] N. Isern,et al. Structure and DNA-binding Sites of the SWI1 AT-rich Interaction Domain (ARID) Suggest Determinants for Sequence-specific DNA Recognition* , 2004, Journal of Biological Chemistry.
[42] A. Perrone,et al. Endometrial carcinoma: past, present, and future , 2021 .
[43] H. Katagiri,et al. Clinicopathologic analysis of loss of AT-rich interactive domain 1A expression in endometrial cancer. , 2013, Human pathology.